Therapy Related Leukemias: Susceptibility, Prevention and Treatment

References

• Perera F P. Environment and Cancer: Who are susceptible?. Science 1997; 278: 1068–1073
   PubMed Web of Science ®Google Scholar
• Park D, Koeffler P. Therapy related myelodysplastic syndromes. Sem Hematol 1996; 33: 256–273
   PubMed Web of Science ®Google Scholar
• Kony S J, de Vathaire F, Chompret A, Shamsaldim A, Grimaud E, Raquin M A, Oberlin O, Brugieres L, Feunteun J, Eschwege F, Chavaudra J, Lemerle J, Bonaiti-Pellie C. Radiation and genetic factors in the risk of second malignant neoplasms after a first cancer in childhood. Lancet 1997; 350: 91–95
   PubMed Web of Science ®Google Scholar
• Brunetti D, Amaro P, Cavalieri F, Stanta G. Cancer risk in first-degree relatives of children with malignant tumours (province of Trieste, Italy). Int J Cancer 1997; 73: 822–27
   PubMed Web of Science ®Google Scholar
• Chen H, Sandier D P, Taylor J A, Shore D L, Liu E, Bloom-field C D, Bell D A. Increased risk for myelodysplastic syndromes in individuals with glutathione transferase theta 1 (GSTT1) gene defect. Lancet 1996; 347: 295–97
   PubMed Web of Science ®Google Scholar
• Larson R A, Wang Y, Banerjee M, Wiemels J, Hartford C, Le Beau M M, Smith M T. Prevalence of the inactivating 609C>T polymorphism in the NAD(P)H: Quinone oxidoreductase (NQO1) gene in patients with primary and therapy and therapy-related myeloid leukemia. Blood 1999; 94: 803–807
   PubMed Web of Science ®Google Scholar
• Pedersen-Bjergaard J, Philip P, Larsen S O, Andersson M, Daugaard G, Ersboll J, Hansen S W, Hou-Jensen K, Nielsen D, Sigsgaard T C. Therapy related myelodysplasia and acute myeloid leukemia. Cytogenetic characteristics of 115 consecutive cases and risk in seven cohort of patients treated intensively for malignant diseases in the Copenhagen series. Leukemia 1993; 7: 1975–86
   PubMed Web of Science ®Google Scholar
• Tarbell N J, Gelber R D, Weinstein H J, Mauch P. Sex differences in risk of second malignand tunours after Hodgkin's disease in childhood. Lancet 1993; 341: 1428–32
   PubMed Web of Science ®Google Scholar
• Kudo K, Yoshida H, Kiyoi H, Numata S, Horibe K, Naoe T. Etoposide-related acute promyelocitic leukemia:. Leukemia 1998; 12: 1171–75
   PubMed Web of Science ®Google Scholar
• Rowley J D, Golomb H M, Vardiman J W. Nonrandom chromosome abnormalities in acute leukemia and dysmyelopoielic syndromes in patients with previously treated malignant diseases. Blood 1981; 58: 759
   PubMed Web of Science ®Google Scholar
• Pedersen-Bjergaard J. Incidence, previous treatment and chromosome characteristics of secondary acute non-lymphocytic leukemia. Cancer Treat Rev 1985; 12: 5–75
   PubMed Web of Science ®Google Scholar
• Rubin C M, Arthur D C, Woods W G, Lange B J, Nowell P C, Rowley J D, Nachman J, Bostrom B, Baum E S, Suarez C R. Therapy-related myelodysplastic syndrome and acute myeloid leukemia in children: correlation between chromosomal abnormalities and prior therapy. Blood 1991; 78: 2982–8
   PubMed Web of Science ®Google Scholar
• Rabbitts T H. Translocations, master genes, and differences between the origins of acute and chronic leukemias. Cell 1991; 67: 641–4
   PubMed Web of Science ®Google Scholar
• Thirman M J, Gill H J, Burnett R C, Mbangkollo D, McCabe N R, Kobayashi H, Ziemin van der Poel S, Kaneko Y, Morgan R, Sandberg A A. Rearrangement of the MLL gene in acute lymphoblastic and acute myeloid leukemias with 1 Iq23 chromosomal translocations. N Engl J Med 1993; 329: 909–14
   PubMed Web of Science ®Google Scholar
• Pedersen-Bjergaard J, Rowley J D. The balanced and the unbalanced chromosome aberrations of acute myeloid leukemia may develop in different ways and may contribute differently to malignant transformation. Blood 1994; 83: 2780–6
   PubMed Web of Science ®Google Scholar
• Felix C A. Secondary leukemias induced by topoisomerase-targeted drugs. Bioch Biophys Acta 1998; 1400: 233–255
   PubMed Web of Science ®Google Scholar
• Kobayashi H, Montgomery K T, Bohlander S K, Adra C N, Lim B L, Kucherlapati R S, Donis-Keller H, Holt M S, Le Beau M M, Rowley J D. Fluorescence in situ hybridization mapping of translocations and deletions involving the short arm of human chromosome 12 in malignant hematologic diseases. Blood 1994; 84: 3473–82
   PubMed Web of Science ®Google Scholar
• Cadman E C, Capizzi R L, Bertino J R. Acute nonlymphocytic leukemia. A delayed complication of Hodgkin's disease therapy: analysis of 109 cases. Cancer 1977; 40: 1280
   PubMed Web of Science ®Google Scholar
• Hawkinns M M, Kinnier Wilson LM, Stoval M A. Epipodophillotoxins, alkylating agents, and radiation and risk of secondary leukaemia after childhood cancer. Brit Med J 1992; 304: 951–58
   PubMed Web of Science ®Google Scholar
• Shulman L N. The biology of alkylating-agent cellular injury. Hematol Oncol Clin North Am 1993; 7: 325–35
   PubMed Web of Science ®Google Scholar
• Kyle R. Second malignancies associated with chemotherapic agents. Semin Oncol 1982; 9: 133
   Google Scholar
• Stott H, Fox W, Girling D J, Stephens R J, Gallon D A. Acute leukaemia after busulphan. Brit Med J 1977; 2: 1513–17
   PubMed Web of Science ®Google Scholar
• Greene M H, Harris E L, Gershenson D M, Malkasian G D, Jr, Melton L J, 3d, Dembo A J, Bennett J M, Moloney W C, Boice J D, Jr. Melphalan may be more potent leukemogen than cyclophospamide. Ann Int Med 1986; 105: 360–67
   PubMed Web of Science ®Google Scholar
• Kantarjian H M, Keating M J, Walters R S, Smith T L, Cork A, McCredie K B, Freireich E J. Therapy related leukemia and myelodisplastic syndrome: Clinical, cytogenetic, and prognostic features. J Clin Oncol 1986; 4: 1748–57
   PubMed Web of Science ®Google Scholar
• Michels S D, McKenna R W, Arthur D C, Brunning R D. Therapy related acute myeloid leukemia and myelodysplastic syndrome. Blood 1985; 65: 1364–72
   PubMed Web of Science ®Google Scholar
• Kouides P A, Bennett J M. Morphology and classification of the myelodysplastic syndromes and their pathologic variants. Sem Hematol 1996; 33: 95–110
   PubMed Web of Science ®Google Scholar
• Pedersen-Bjergaard J, Andersen M K. Secondary or therapy-related myelodysplasia and acute myeloid leukemia and their chromosome aberrations: important to study but difficult to estabilishcausality. Haematologica 1998; 83: 481–2
   PubMedGoogle Scholar
• Dohner K, Brown J, Hehmann U, Hetzel C, Stewart J, Lowther G, Scholl C, Frohling S, Cuneo A, Tsui L C, Lichter P, Scherer S W, Dohner H. Molecular cytogenetic characterization of a critical region in bands 7q35-q36 commonly deleted in malignant myeloid disorders. Blood 1998; 92: 4031–35
   PubMed Web of Science ®Google Scholar
• Pedersen-Bjergaard J, Pedersen M, Roulston D, Philip P. Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia. Blood 1995; 86: 3542–52
   PubMed Web of Science ®Google Scholar
• Merlat A, Lai J L, Sterkers Y. Therapy-related myelodysplastic syndrome and acute myeloid leukemia with 17p deletion. A report on 25 cases. Leukemia 1999; 13: 250–57
   PubMed Web of Science ®Google Scholar
• Kaneko Y, Maseki N, Sakurai M, Shibuya A, Shinohara T, Fujimoto T, Kanno H, Nishikawa A. Chromosome pattern in juvenile chronic myelogenous leukemia, myelodysplastic syndrome, and acute leukemia associated with neurofibromatosis. Leukemia 1989; 3: 36–41
   PubMed Web of Science ®Google Scholar
• Perilongo G, Felix C A, Meadows A T, Nowell P, Biegel J, Lange B J. Sequential development of Wilms tumor. T-cell acute lymphoblastic leukemia, medulloblastoma and myeloid leukemia in a child with type 1 neurofibromatosis: a clinical and cytogenetic case report. Leukemia 1993; 7: 912–5
   PubMed Web of Science ®Google Scholar
• Mans J M, Wiersma S R, Mahgoub N, Thompson P, Geyer R J, Hurwitz C G, Lange B J, Shannon K M. Monosomy 7 myelodysplastic syndrome and other second malignant neoplasms in children with neurofibromatosis type 1. Cancer 1997; 79: 1438–46
   PubMed Web of Science ®Google Scholar
• Side L, Taylor B, Cayouette M, Conner E, Thompson P, Luce M, Shannon K. Homozygous inactivation of the NF1 gene in bone marrow cells from children with neurofibromatosis type 1 and malignant myeloid disorders. N Engl J Med 1997; 336: 1713–20
   PubMed Web of Science ®Google Scholar
• Mahgoub N, Taylor B R, Gratiot M, Kohl N E, Gibbs J B, Jacks T, Shannon K M. Myeloid malignancies induced by alkylating agents in Nfl mice. Blood 1999; 93: 3617–23
   PubMed Web of Science ®Google Scholar
• Willman C L, Sever C E, Pallavicini M G, Harada H, Tanaka N, Slovak M L, Yamamoto H, Harada K, Meeker T C, List A F. Deletion of IRF-1, mapping to chromosome 5q31.1, in human leukemia and preleukemic myelodysplasia. Science 1993; 259: 968–71
   PubMed Web of Science ®Google Scholar
• Lane D P. p53: Guardian of genome. Nature 1992; 358: 15–17
   PubMed Web of Science ®Google Scholar
• Felix C A, Hosier M R, Provisor D, Salhany K, Sexsmith E A, Slater D J, Cheung N K, Winick N J, Strauss E A, Heyn R, Lange B J, Malkin D. The p53 gene in pediatric therapy-related leukemia and myelodysplasia. Blood 1996; 87: 4376–81
   PubMed Web of Science ®Google Scholar
• Diller L, Sexsmith E, Gottlieb A, Li F P, Malkin D. Germline p53 mutations are frequently detected in young children with rhabdomyosarcoma. J Clin Invest 1995; 95: 1606–11
   PubMed Web of Science ®Google Scholar
• Zhu Y M, Das-Gupta E P, Russel N H. Microsatellite instability and p53 mutations are associated with abnormal expression of the MSH2 gene in adult acute leukemia. Blood 1999; 94: 733–40
   PubMed Web of Science ®Google Scholar
• Fishel R, Ewel A, Lee S, Lescoe M K, Griffith J. Binding of mismatched microsatellite DNA sequences by the human MSH2 protein. Science 1994; 266: 1403
   PubMed Web of Science ®Google Scholar
• Liu B, Parsons R E, Hamilton S R, Petersen G M, Lynch H T, Watson P, Markowitz S, Willson J K, Green J, de la Chapelle A. hMSH2 mutations in hereditary nonpolyposis corectal cancer childrens. Cancer Res 1994; 54: 4590
   PubMed Web of Science ®Google Scholar
• Felix C A, Megonigal M D, Chervinsky D S, Leonard D G, Tsuchida N, Kakati S, Block A M, Fisher J, Grossi M, Salhany K I, Jani-Sait S N, Apian P D. Association of germ-line p53 mutation with MLL segmental jumping translocation in treatment-related leukemia. Blood 1998; 91: 4451–6
   PubMed Web of Science ®Google Scholar
• Tanaka K, Arif M, Eguchi M, Kyo T, Dohy H, Kamada N. Frequent jumping translocations of chromosomal segments involving the ABL oncogene alone or in combination with CD3-MLL genes in secondary leukemias. Blood 1997; 89: 596–600
   PubMed Web of Science ®Google Scholar
• Long B J. Mechanism of action of teniposide (VM 26) and comparison with etoposide (VP16). Sem Oncol 1992; 4: 325–45
   Google Scholar
• Sandoval C, Pui C H, Bowman L C, Heaton D, Hurwitz C A, Raimondi S C, Behm F G, Head D R. Secondary acute myeloid leukemia in children previously treated with alkylating agents, intercalating topoisomerase II inhibitors, and irradiation. J Clin Oncol 1993; 11: 1039–1045
   PubMed Web of Science ®Google Scholar
• Megonigal M D, Rappaport E F, Jones D H, Kim C S, Nowell P C, Lange B J, Felix C A. Panhandle PCR strategy to amplify MLL genomic breakpoints in treatment-related leukemias. Proc Natl Acad Sci 1997; 94: 11583–88
   PubMed Web of Science ®Google Scholar
• Quesnel B, Kantarjian H, Bjergaard J P, Brault P, Estey E, Lai J L, Tilly H, Stoppa A M, Archimbaud E, Harousseau J L. Therapy-related acute myeloid leukemia with t(8,21), inv(16), and t(8,16): a report on 25 cases and review of the literature. J Clin Oncol 1993; 11: 2370–9
   PubMed Web of Science ®Google Scholar
• Kumar L. Epipodophyllotoxins and secondary leukaemia. Lancet 1993; 342: 819–820
   PubMed Web of Science ®Google Scholar
• Pedersen-Bjergaard J, Brondum-Nielsen K, Karle H, Johansson B. Chemotherapy-related - late occurring - Philadelphia chromosome in AML, ALL and CML. Similar events related to treatment with DNA topoisomerase II inhibitors?. Leukemia 1997; 11: 1571–4
   PubMed Web of Science ®Google Scholar
• Hawkins M M, Wilson L M, Stovall M A, Marsden H B, Potok M H, Kingston J E, Chessells J M. Epipophyllotoxins, alkylating agents, and radiation and risk of secondary leukaemia after childhood cancer. Brit Med J 1992; 304: 951–58
   PubMed Web of Science ®Google Scholar
• Pui C H, Ribeiro R C, Hancock M L, Rivera G K, Evans W E, Raimondi S C, Head D R, Behm F G, Mahmoud M H, Sandlund J T, Crist W M. Acute myeloid leukemia in children treated with epipodophillotoxins for acute lymphocytic leukemia. N Engl J Med 1991; 325: 1682–87
   PubMed Web of Science ®Google Scholar
• Pui C H, Relling M V, Behm F G, Hancock M L, Boyett J M, Raimondi S C, Krance R A, Mahmoud H H, Ribeiro R C, Sand-lund J T, Head D R, Ewans W E, Crist W M, Rivera G K. L-asparaginase may potentiate the leukemogenic effect of epipodophyllotoxins. Leukemia 1995; 9: 1680–84
   PubMed Web of Science ®Google Scholar
• Ratain M J, Kaminer L S, Bitran J D, Larson R A, Le Beau M M, Skosey C, Purl S, Hoffman P C, Wade J, Vardiman J W. Acute nonlymphocytic leukemia following etoposide and cisplatin combination chemotherapy for advanced non-small cell carcinoma of the lung. Blood 1987; 70: 1421–17
   Google Scholar
• Smith M A, Rubinstein L, Anderson J R, Arthur D, Catalano P J, Freidlin B, Heyn R, Khayat A, Krailo M, Land V J, Miser J, Shuster J, Vena. Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins. J Clin Oncol 1999; 17: 569–577
   PubMed Web of Science ®Google Scholar
• Relling M V, Yanishevski Y, Nemec J, Evans W E, Boyett J M, Behm F G, Pui C H. Etoposide and antimetabolite pharmacology in patients who develop secondary acute myeloid leukemia. Leukemia 1998; 12: 346–52
   PubMed Web of Science ®Google Scholar
• Felix C A, Walker A H, Lange B J, et al. Association of CYP3A4 genotype with treatment related leukemia. Proc Natl Acad Sci 1998; 95: 13176–81
   PubMed Web of Science ®Google Scholar
• Andersen M K, Johanson B, Larsen S O, Pedersen-Bjergaard J. Chromosomal abnormalities in secondary MDS and AML. Relationship to drugs and radiation with specific emphasis on the balanced rearrangements. Haematologica 1998; 83: 483–488
   PubMed Web of Science ®Google Scholar
• Hoffmann L, Moller P, Pedersen-Bjergaard J, Waage A, Pedersen M, Hirsch F R. Therapy-related acute promyelocytic leukemia with t(15,17) (q22.q12) following chemotherapy with drugs targeting DNA topoisomerase II. A report of two cases and a review of the literature. Ann Oncol 1995; 6: 781–8
   PubMed Web of Science ®Google Scholar
• Roulston D, Espinosa R, 3rd, Nucifora G, Larson R A, Le Beau M M, Rowley J D. CBFA2 (AML1) translocations with novel partner chromosomes myeloid leukemias: association with prior therapy. Blood 1998; 92: 2879–85
   PubMed Web of Science ®Google Scholar
• Gamou T, Kitamura E, Hosoda F, Shimizu K, Shinohara K, Hayashi Y, Nagase T, Yokoyama Y, Ohki M. The partner gene of AML1 in t(16;21) myeloid malignancies in a novel member of the MTGS(ETO) family. Blood 1998; 91: 4028–37
   PubMed Web of Science ®Google Scholar
• Corral J, Lavenir I, Impey H, Warren A J, Forster A, Larson T A, Bell S, McKenzie A N, King G, Rabbitts T H. An MII-AF9 fusion gene made by homologous recombination causes acute leukemia in chimeric mice: a method to create fusion oncogenes. Cell 1996; 85: 853–61
   PubMed Web of Science ®Google Scholar
• Hunger S P, Tkachuk D C, Amylon M D, Link M P, Carroll A J, Welborn J L, Willman C L, Cleary M L. HRX involvement in de novo and secondary leukemias with diverse chromosome 11q23 abnormalities. Blood 1993; 81: 3197–203
   PubMed Web of Science ®Google Scholar
• Broeker P L, Super H G, Thirman M J, Pomykala H, Yonebayashi Y, Tanabe S, Zeleznik Le N, Rowley J D. Distribution of 11q23 breakpoints within the MLL breakpoint cluster region in de novo acute leukemia and in treatment-related acute myeloid leukemia: correlation with scaffold attachment regions and topoisomerase II consensus binding sites. Blood 1996; 87: 1912–22
   PubMed Web of Science ®Google Scholar
• Felix C A, Winick N J, Negrini M, Bowman W P, Croce C M, Lange B J. Common region of ALL-1 gene disrupted in epipodophyllotoxin-related secondary acute myeloid leukemia. Cancer Res 1993; 53: 2954–6
   PubMed Web of Science ®Google Scholar
• Bower M, Parry P, Gibbons B, Amess J, Lister T A, Young B D, Evans G A. Human trithorax gene rearrangements in therapy-related acute leukaemia after etoposide treatment. Leukemia 1994; 8: 226–9
   PubMed Web of Science ®Google Scholar
• Felix C A, Hosier M R, Winick N J, Masterson M, Wilson A E, Lange B J. ALL-J gene rearrangements in DNA topoisomerase II inhibitor-related leukemia in children. Blood 1995; 85: 3250–56
   PubMed Web of Science ®Google Scholar
• Strissel P L, Strick R, Rowley J D, Zeleznik-Le N J. An in vivo topoisomerase II cleavage site and DNase 1 Hypersensitive site clocalize near exon 9 in the MLL breakpoint cluster region. Blood 1998; 92: 3793–3803
   PubMed Web of Science ®Google Scholar
• Stanulla M, Wang J, Chervinsky Apian PD. Topoisomerase II inhibitors induce DNA double strand breaks at a specific site within the AML1 locus. Leukemia 1997; 11: 490–6
   PubMed Web of Science ®Google Scholar
• Le Beau M M, Albain K S, Larson R A, Vardiman J W, Davis E M, Blough R R, Golomb H M, Rowley J D. Clinical and cytogenetic correlation in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7. J Clin Oncol 1986; 4: 325–45
   PubMed Web of Science ®Google Scholar
• Pollicardo N, O'Brien S, Estey E H, Al-bitar M, Pierce S, Keating M, Kantarajian H M. Secondary acute promyelocytic leukemia. Characteristics and prognosis of 14 patientsn from a single institution. Leukemia 1996; 10: 27–31
   PubMed Web of Science ®Google Scholar
• Pulsoni A, Pagano L, Mele L, Avvisati G, Visani G, Zagonel V, Barbui T, Petti M C, Kropp M, Ciolli S, Cerri R, Nosari A M, Pogliani E, Allione B, Di Bona E, Invemizzi R, Melillo L, Coser P, Leone G, Mandelli F, on behalf of Italian Cooperative Group GIME. M. A. Acute promyelocytic leukemia following previous malignancy. Report of 51 cases. Blood 1999; 94(suppl. 1)697a, abstract 3083
   Google Scholar
• Xue Y, Lu D, Guo Y, Lin B. Specific chromosomal translocations and therapy-related leukemia induced by bimolane therapy for psoriasis. Leukemia Res 1992; 16: 1113–23
   PubMed Web of Science ®Google Scholar
• Pedersen-Bijergard J. Acute promyelocytic leukemia with K15–17) following inhibition of DNA topoisimerase II. Ann Oncol 1995; 6: 751–53
   PubMed Web of Science ®Google Scholar
• Wiernik P H, Muse I M. Acute promyelocytic leukemia after treatment of malignant glioma in a patient with Von Recklinghausen's disease: case report and revue of literature. Leukemia 1996; 10: 178–199
   PubMed Web of Science ®Google Scholar
• Pagano L, Pulsoni A, Tosti M E, Annino L, Mele A, Camera A, Martino B, Guglielmi C, Cerri R, Invernizzi R, Vastagnola C, Bassan R, Mele L, Todeschini G, Leone G, Mandelli F. Acute lymphoblastic leukaemia occurring as second malignancy; report of the GIMEMA Archive of Adult Acute Leukaemia. Brit J Hemat 1999; 106: 1037–40
   PubMed Web of Science ®Google Scholar
• Archimbaud E, Charrin C, Guyotat D, Magaud J P, Gentil-homme O, Fiere D. Acute leukaemia with t(4;11) in patients previously exposed to carcinogens. Brit J Haemal 1988; 69: 467–70
   PubMed Web of Science ®Google Scholar
• Jonveaux P, Million J, Bernard O, Le Coniat M, Derre J, Flexor M, Larsen C J, Berger R. Distinct MLL gene rearrangements associated with successive acute monocytic and lymphoblastic leukemias in the same patient. Leukemia 1994; 8: 2224–27
   PubMed Web of Science ®Google Scholar
• Seeker-Walker L M, Moorman A V, Bain B J, Mehta A B. Secondary acute leukemia and myelodysplastic syndrome with 11q23 abnormalities. Leukemia 1998; 12: 840–44
   PubMed Web of Science ®Google Scholar
• Teichmann J V, Sieber G, Ludwig W D, Karow J, Ruehl H. Chronic myelocytic leukemia as a second neoplasia in the course of chronic myelogenous leukemia. Case report and revue of literature. Leukemia Res 1986; 10: 361–68
   PubMed Web of Science ®Google Scholar
• Cazzola M, Bergamaschi G, Melazzini M, Ponchio L, Rosti V, Molinari E. Chronic myelogenous leukemia following radiotherapy and chemotherapy for non-Hodgkin lymphoma. Haematologica 1990; 75: 477–79
   PubMedGoogle Scholar
• Aguiar R CT. Therapy related chronic myeloid leukemia: An epidemiological, clinical and pathogenetic appraisal. Leukemia & Lymphoma 1998; 29: 17–26
   PubMed Web of Science ®Google Scholar
• Thirman M J, Larson R A. Therapy related myeloid leukemia. Hematol/Oncol Clin North Am 1996; 10: 293–317
   PubMed Web of Science ®Google Scholar
• Valagussa P, Bonadonna G. Hodgkin's disease and risk of acute leukemia in succesfully treated patients. Haematologica 1998; 83: 769–70
   PubMedGoogle Scholar
• Blayney D W, Longo D L, Young R C, Greene M H, Hubbard S M, Postal M G, Duffey P L, DeVita V T, Jr. Decreasing risk of leukemia with prolonged follow-up after chemotherapy and radiotherapy for Hodgkin's disease. N Engl J Med 1987; 316: 710–14
   PubMed Web of Science ®Google Scholar
• Sankila R, Garwicz S, Olsen J H, Dollner H, Hertz H, Kreuger A, Langmark F, Lanning M, Moller T, Tulinius H. Risk of subsequent malignant neoplasms among 1,641 Hodgkin's disease patients diagnosed in childhood and adolescence: a population-based cohort study in the five nordic countries. J Clin Oncol 1996; 14: 1442–45
   PubMed Web of Science ®Google Scholar
• Pedersen-Biergaard J, Larsen S O. Incidence of acute nonlymphocytic leukemia, preleukemia, and acute myelopro-liferative syndrome up to 10 years after treatment of Hodgkin's disease. N Engl J Med 1982; 307: 965–71
   PubMed Web of Science ®Google Scholar
• Andrieu J M, Ifrah N, Payen C, Fermanian J, Coscas Y, Flandrin G. Increased risk of secondary acute nonlymphocytic leukemia after extended-field radiation therapy combined with MOPP chemotherapy for Hodgkin's disease. J Clin Oncol 1990; 8: 1148–54
   PubMed Web of Science ®Google Scholar
• van Leeuwen F E, Klokman W J, Hagenbeek A, Noyon R, van den Belt-Dusebout A W, van Kerkhoff E H, van Heerde P, Somers R. Second cancer risk following Hodgkin's disease: a 20-year follow-up study. J Clin Oncol 1994; 12: 312–25
   PubMed Web of Science ®Google Scholar
• Schellong G, Riepenhausen M, Creutzig U, Ritter J, Harbott J, Mann G, Gadner H. Low risk of secondary leukemias after chemotherapy without mechlorethamine in childhood Hodgkin's disease. J Clin Oncol 1997; 15: 2247–53
   PubMed Web of Science ®Google Scholar
• Henry-Amar M, Dietrich P Y. Acute leukemia after the treatment of Hodgkin's disease. Hematol Oncol Clin North Am 1993; 7: 369–387
   PubMed Web of Science ®Google Scholar
• Cimino G, Papa G, Tura S, Mazza P, Rossi Ferrini PL, Bosi A, Amadori S, Lo Coco F, D'Arcangelo E, Giannarelli D. Primary cancer following Hodgkin's disease. Updated results of an Italian multicentric study. J Clin Oncol 1991; 9: 432–7
   PubMed Web of Science ®Google Scholar
• Devereux S, Selassie T G, Hudson Vaughan G, Hudson Vaughan B, Linch D C. Leukemia complicating treatment for Hodgkin's disease. The experience of the British National Lymphoma Investigation. Brit Med J 1990; 301: 1077–80
   PubMed Web of Science ®Google Scholar
• Brusamolino E, Anselmo A P, Klersy C, Santoro M, Orlandi E, Pagnucco G, Lunghi F, Maurizi-Enrici R, Baroni C D, Lazzarino M, Mandelli F, Bernasconi C. The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher after combined modality programs than after chemotherapy alone and is correlated with the extend of radiotherapy and type and duration of chemotherapy, a case control study. Haematologica 1998; 83: 812–823
   PubMed Web of Science ®Google Scholar
• Travis L B, Curtis R E, Stovall M, Holowaty E J, van Leeuwen F E, Glimelius B, Lynch C F, Hagenbeek A, Li C Y, Banks P M. Risk of leukemia following treatment for non-Hodgkin's lymphoma. J Natl Cancer Instit 1994; 86: 1450–57
   PubMed Web of Science ®Google Scholar
• Pedersen-Bjergaard J, Ersboll J, Sorensen H M, Keiding N, Larsen S O, Philip P, Larsen M S, Schultz H, Nissen N I. Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin's lymphomas. Ann Int Med 1985; 103: 195–200
   PubMed Web of Science ®Google Scholar
• Lavey R S, Eby N L, Prosnitz L R. Impact on second malignancy risk of combined use of radiation and chemotherapy for lymphoma. Cancer 1990; 66: 80–88
   PubMed Web of Science ®Google Scholar
• Orlandi E, Lazzarino M, Bernasconi P, Astori C, Bernasconi C. Secondary acute myeloid leukemia following treatment with VP 16-containing regimens for non-Hodgkin's lymphoma. Haematologica 1998; 83: 758–59
   PubMed Web of Science ®Google Scholar
• Bergsagel D E, Bailey A J, Langley G R, MacDonald R N, White D F, Miller A B. The chemotherapy of plasma cell myeloma and the incidence of acute leukemia. N Engl J Med 1979; 301: 743–48
   PubMed Web of Science ®Google Scholar
• Cuzick J, Erskine S, Edelman D, Gallon D A. A comparison of the incidence of the myelodisplasic syndrome and acute myeloid leukaemia following melphalan and cyclophosphamide treatement for myelomatosis. Brit J Cancer 1987; 55: 523–529
   PubMed Web of Science ®Google Scholar
• Govindarajan R, Jagannath S, Flick J T, Vesole D H, Sawyer J, Barlogie B, Tricot G. Preceding slandard therapy is the likely cause of MDS after autotransplants for myeloma. Brit J Haemut 1996; 95: 349–53
   PubMed Web of Science ®Google Scholar
• Pui C H, Behm F G, Raimondi S C, Dodge R K, George S L, Rivera G K, Mirro J, Jr, Kalwinsky D K, Dahl G V, Murphy S B. Secondary acute mycloid leukemia in children treated for acute lymphoid leukemia. N Engl J Med 1989; 321: 136–42
   PubMed Web of Science ®Google Scholar
• Neglia J P, Meadows A T, Rohison L L, Kim T H, Newton W A, Ruymann F B, Sather H N, Hammond G D. Second neoplasms after acute lymphohlastic leukemia in childhood. N Engl J Med 1991; 325: 1330–1336
   PubMed Web of Science ®Google Scholar
• Kreissman S G, Gelber R D, Cohen H J, Clavell L A, Leavitt P, Sallan S E. Incidence of secondary acute myelogenous leukemia after treatment of childhood acute lymphohlastic leukemia. Cancer 1992; 70: 2208–2213
   PubMed Web of Science ®Google Scholar
• Jankovic M, Fraschini D, Amici A, Arico M, Arrighini A, Basso G, Colella R, DiTullio M T, Haupt R, Macchia P. Outcome after cessation of therapy in childhood acute lymphoblastic leukaemia. Eur J Cancer 1993; 13: 1839–1843
   Web of Science ®Google Scholar
• Pagano L, Annino L, Ferrari A, Camera A, Martino B, Montillo M, Tosti M E, Mele A, Pulsoni A, Vegna M L, Leone G, Mandelli F. Secondary haematological neoplasm after treatment of adult acute lymphoblastic leukaemia, analysis of 1170 adult ALL patients enrolled in the GIMEMA trials. Br J Haematol 1998; 100: 669–76
   PubMed Web of Science ®Google Scholar
• Najean Y, Rain J D. Treatment of polycythemia vera. the use of hydroxyurea and piprobroman in 292 patients under the age of 65 years. Blood 1997; 90: 3370–7
   PubMed Web of Science ®Google Scholar
• Sterkers Y, Preudhomme C, Lai J L, Demory J L, Caulier M T, Wattel E, Bordessoule D, Bauters F, Fenaux P. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea. high proportion of cases with 17p deletion. Blood 1998; 91: 616–22
   PubMed Web of Science ®Google Scholar
• Petti M C, Spadea A, Avvisati G, Spadea T, Latagliata R, Montefusco E, Cosenza M, Malagnino F. Polycytemia vera treated with pipobroman as single agent, low incidence of secondary leukemia in a cohort of patients observed during 20 years (1971–91). Leukemia 1998; 12: 869–74
   PubMed Web of Science ®Google Scholar
• Barosi G, Ambrosetti A, Centra A, Falcone A, Finelli C, Foa P, Grossi A, Guarnone R, Rupoli S, Luciano L, Petti M C, Pogliani E, Russo D, Ruggeri M, Quaglini S. Splenectomy and risk of blast transformation in myelofibrosis with myeloid metaplasia. Blood 1998; 91: 3630–36
   PubMed Web of Science ®Google Scholar
• Robertson L E, Estey E, Kanlarjian H, Koller C, O'Brien S, Brown B, Keating M J. Therapy related leukemia and myelodysplastic syndrome in chronic lymphocyte leukemia. Leukemia 1994; 8: 2047–51
   PubMed Web of Science ®Google Scholar
• Kampmeier P, Spielberger R, Dickstein J, Mick R, Golomb H, Vardiman J W. Increased incidence of second neoplasms in patients treated with interferon alfa for hairy cell leukemia. A clinicopathologic assessment. Blood 1994; 83: 2931–38
   PubMed Web of Science ®Google Scholar
• Au W Y, Klasa R J, Gallagher R, Le N, Gascoyne R D, Connors J M. Second malignancies in patients with hairy cell leukemia in British Columbia. A 20 year expeience. Blood 1998; 92: 1160–64
   PubMed Web of Science ®Google Scholar
• Carey R W, Holland J F, Sheghe P R, Grahams S. Association of cancer of the breast and acute myelocytic leukemia. Cancer 1967; 20: 1988–93
   Web of Science ®Google Scholar
• Fisher B, Rockette H, Fisher E R, Wickerham D L, Redmond C, Brown A. Leukemia in breast cancer patients following adjuvant chemotherapy or post-operative radiation. the NSABP experience. J Clin Oncol 1985; 3: 1640–58
   PubMed Web of Science ®Google Scholar
• Curtis R E, Boice J D, Jr, Stovall M, Bernstein L, Greenberg R S, Flannery J T, Schwartz A G, Weyer P, Moloney W C, Hoover R N. Risk of leukemia after chemotherapy and radiation treatment for breast cancer. N Engl J Med 1992; 326: 1745–51
   PubMed Web of Science ®Google Scholar
• Tallman M S, Gray R, Bennett J M, Variakojis D, Robert N, Wood W C, Rowe J M, Wiernik P H. Leukemogenic potential of adjuvant chemotherapy for early-stage breast cancer, the eastern cooperative oncology group experiencre. J Clin Oncol 1995; 13: 1557–63
   PubMed Web of Science ®Google Scholar
• De Cillis A, Anderson S, Wckerham D. Acute myeloid leukemia (AMD in NSABPT B25. Proc Am Soc Clin Oncol 1997; 130a, abstract 459
   Google Scholar
• Diamandidou E, Buzdar A U, Smith T L, Frye D, Witjaksono M, Hortobagyi G N. Treatment related leuekmia in breast cancer patients treated with fluorouracil-doxorubicin-cyclophosphamide combination adjuvant chemotherapy. The University of Texas M. D. Anderson Cancer Center experience. J Clin Oncol; 1996; 14: 2722–30
   PubMed Web of Science ®Google Scholar
• Andersson M, Philip P, Pedersen-Bijergard J. High risk of therapy related leukemia and preleukemia after therapy with prednimustine. methotrexate, 5-fluorouracile, mithoxantrone and tamoxifene for advanced cancer. Cancer 1990; 65: 2460–64
   PubMed Web of Science ®Google Scholar
• Coleman M P, Bell C MJ, Fraser P. Second primary malignancy after Hodgkin's disease, ovarian cancer and cancer of the testis. a population-based cohort study. Br J Cancer 1987; 56: 349–355
   PubMed Web of Science ®Google Scholar
• Pedersen-Bjergaard J, Nissen N I, Sorensen H M, Hou-Jensen K, Larsen M S, Ernst P, Ersbol J, Knudtzon S, Rose C. Acute non lymphocitic leukemia in patients with ovarian carcinoma following long term treatment with treosulfan (dihy-droxybusulfan). Cancer 1980; 45: 19–29
   PubMed Web of Science ®Google Scholar
• Travis L B, Holowaty E J, Bergfeldt K, Lynch C F, Kohler B A, Wiklund T, Curtis R E, Hall P, Andersson M, Pukkala E, Sturgeon J, Stovall M. Risk of leukemia after platinum-based chemotherapy for ovarian cancer. N Engl J Med 1999; 340: 351–7
   PubMed Web of Science ®Google Scholar
• Pedersen-Bjergaard J, Daugaard G, Hansen S W, Philip P, Larsen S O, Rorth M. Increased risk of myelodisplasia and leukemia after etoposide, cisplatin, and bleomycin for germ-cell tumours. Lancet 1991; 338: 359–63
   PubMed Web of Science ®Google Scholar
• Kollmannsberger C, Kollmannsberger C, Beyer J, Droz J P, Harstrick A, Hartmann J T, Biron P, Flechon A, Schoffski P, Kuczyk M, Schmoll H J, Kanz L, Bokemeyer C. Secondary leukemia following high cumulative doses of etoposide in patients treated for advanced germ cell tumors. J Clin Oncol 1998; 16: 3386–91
   PubMed Web of Science ®Google Scholar
• Travis L B, Curtis R E, Storm H, Hall P, Holowaty E, Van Leeuwen F E, Kohler B A, Pukkala E, Lynch C F, Andersson M, Bergfeldt K, Clarke E A, Wiklund T, Stoter G, Gospodarowicz M, Sturgeon J, Fraumeni J F, Jr, Boice J D, Jr. Risk of second neoplasms among long-term survivors of testicular cancer. J Nat Cancer Inst 1997; 89: 1429–39
   PubMed Web of Science ®Google Scholar
• Schneider D T, Higenfeld E, Scwabe D, Behnisch W, Zoubek A, Wessalowski R, Gobel U. Acute myelogenous leukemia after treatment for malignant germ cell tumors in children. J Clin Oncol 1999; 10: 3226–33
   Google Scholar
• Stone R M, Neuberg D, Soiffer R, Takvorian T, Whelan M, Rabinowe S N, Aster J C, Leavitt P, Mauch P, Freedman A S. Myelodisplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 1994; 12: 2535–42
   PubMed Web of Science ®Google Scholar
• Miller J S, Arthur D C, Litz C E, Neglia J P, Miller W J, Weisdorf D J. Myelodisplastic syndrome after autologous bone marrow transplantation, an additional late complication of curative cancer therapy. Blood 1994; 12: 3780–86
   Google Scholar
• Roman-Unfer S, Bitran J D, Hanauer S, Johnson L, Rita D, Booth C, Chen K. Acute myeloid leukemia and myelodisplasia following intensive chemotherapy for breast cancer. Bone Marrow Transpl 1995; 16: 163–68
   PubMed Web of Science ®Google Scholar
• Sica S, Salutari P, Ciarli M, Piccirillo N, Laurenti L, Menichella G, Leone G. Secondary leukemia after autologous peripheral progenitor cell transplantation for breast cancer. Leukemia 1997; 11: 1990–92
   PubMed Web of Science ®Google Scholar
• Milligan D W, Ruiz De Elvira M C, Kolb H J, Goldstone A H, Meloni G, Rohatiner A Z, Colombat P, Schmitz N. Secondary leukaemia and myelodysplasia after autografting for lymphoma. results from the EBMT. EBMT Lymphoma and Late Effects Working Parties. European Group for Blood and Marrow Transplantation. Br J Haematol 1999; 106: 1020–6
   PubMed Web of Science ®Google Scholar
• Pedersen-Bijergard J, Pedersen M, Myhre Geisler C. High risk of therapy related leukemia after BEAM chemotherapy and autologous stem cell transplantation for previously treated lymphoma is mainly related to primary chemotherapy and not to the BEAM-transplantation procedure. Leukemia 1997; 11: 1654–60
   PubMed Web of Science ®Google Scholar
• Andre M, Henry-Amar M, Blaise D, Colombat P, Fleury J, Milpied N, Cahn J Y, Pico J L, Bastion Y, Kuentz M, Nedellec G, Altai M, Ferme C, Gisselbrecht C. Treatment related deaths and second cancer risk after autologous stem-cell transplantation for Hodgkin's disease. Blood 1998; 92: 1933–40
   PubMed Web of Science ®Google Scholar
• Laughlin M J, McGaughey D S, Crews J R, Chao N J, Rizzieri D, Ross M, Gockerman J, Cirrincione C, Berry D, Mills L, Defusco P, LeGrand S, Peters W P, Vredenburgh J J. Secondary myelodysplasia and acute leukemia in breast cancer patients after autologous bone marrow transplant. J Clin Oncol 1998; 16: 1008–12
   PubMed Web of Science ®Google Scholar
• Deeg H J, Sociè G. Malignancies after hematopoietic stem cell transplantation. Many questions, some answers. Blood 1998; 91: 1833–44
   PubMed Web of Science ®Google Scholar
• Willman C L. Molecular genetic features of myelodysplastic syndromes (MDS). Leukemia 1998; 12(suppl 1)S2–S6
   PubMedGoogle Scholar
• Ben-Yehuda D, Krichevsky S, Caspi O, Rund D, Polliack A, Abeliovich D, Zelig O, Yahalom V, Paltiel O, Or R, Peretz T, Ben-Neriah S, Yehuda O, Rachmilewitz E A. Microsatellite instability and p53 mutations in therapy related leukemia suggest mutator phenotype. Blood 1996; 88: 4296–4303
   PubMed Web of Science ®Google Scholar
• Mott M G, Boyse J, Hewitt M, Radford M. Do mutations at the glycophorin locus in patients treated for childhood Hodgkin's disease predict secondary leukemia?. Lancet 1994; 343: 828–29
   PubMed Web of Science ®Google Scholar
• Mach-Pascual S, Legare R D, Lu D, Kroon M, Neuberg D, Tantravahi R, Stone R M, Freedman A S, Nadler L M, Gribben J G, Gilliland D G. Predictive value of clonality assay in patients with non-Hodgkin's lymphoma undergoing autologous bone marrow transplant, a single institution study. Blood 1998; 91: 4496–503
   PubMed Web of Science ®Google Scholar
• Cachia P G, Taylor C, Thompson P W, Tennant G B, Masters G, Pettersson T, Whittaker J A, Burnett A K, Jacobs A, Padua R A. Non dysplastic myelodysplasia?. Leukemia 1994; 8: 677–81
   PubMed Web of Science ®Google Scholar
• Karp J E, Smith M A. Modifying risks of secondary leukemias. Is drug scheduling important?. J Nat Cancer Instit 1996; 88: 1787–89
   PubMed Web of Science ®Google Scholar
• Stankovic T, Kidd A M, Sutcliffe A, McGuire G M, Robinson P, Weber P, Bedenham T, Bradwell A R, Easton D F, Lennox G G, Haites N, Byrd P J, Taylor A M. ATM mutations and phenotypes in ataxia-telengiectasia families in the British Isles. Expression of mutant ATM and the risk of leukemia, lymphoma and breast cancer. Am J Human Genet 1998; 62: 334–35
   PubMed Web of Science ®Google Scholar
• Zipursky A, Thorner P, De Harven E, Christensen H, Doyle J. Myelodysplasia and acute megakaryoblastic leukemia in Down's syndrome. Leukemia Res 1994; 18: 163–71
   PubMed Web of Science ®Google Scholar
• Taylor A MR. Ataxia telangiectasia genes and predisposition to leukaemia, lymphoma and breast cancer. Brit J Cancer 1992; 66: 5–9
   PubMed Web of Science ®Google Scholar
• German J. Bloom syndrome, a Mendellian prototype of somatic mutational disease. Medicine 1993; 76: 393–405
   Google Scholar
• Butturini A, Gale R P, Verlander P C, Adler-Brecher B, Gillio A P, Auerbach A D. Hematologic abnormalities in Fanconi anemia, an International Fanconi Anemia Registry Study. Blood 1994; 84: 1650–54
   PubMed Web of Science ®Google Scholar
• Stiller C A, Chessells J M, Fitchett M. Neurofibromatosis and childhood leukaemia/lymphoma a population-based UKCCSG study. Brit J Cancer 1994; 70: 969–72
   PubMed Web of Science ®Google Scholar
• Chen C L, Fuscoe J C, Liu Q, Pui C H, Mahmoud H H, Relling M V. Relationship between cytotxicity and site specific DNA recombination after in vivo exposure of leukemia cells to etoposide. J Nat Cancer Instit 1996; 88: 1840–4
   PubMed Web of Science ®Google Scholar
• Estey E H. Prognosis and therapy of secondary myelodysplastic syndromes. Haematologica 1998; 83: 543–549
   PubMed Web of Science ®Google Scholar
• Levine E G, Bloomfield C D. Leukemia and myelodysplastic syndromes secondary to drug, radiation, and environmental exposure. Semin Oncol 1992; 19: 14–24
   Google Scholar
• Beran M. Treatment of myelodysplastic syndromes. Therapy of Hematopoietic Neoplasia, E Freireich, H Kantarjian. Marcel Dekker, New York, NY 1991; 35
   Google Scholar
• Koeffler H P, Heitjan D, Mertelsmann R, Kolitz J E, Schulman P, Itri L, Gunter P, Besa E. Randomized study of 13-cis retinoic acid vs placebo in myelodysplastic disorders. Blood 1988; 71: 703–708
   PubMed Web of Science ®Google Scholar
• Leone G, Sica S, Ortu La Barbera E, Testa U, Riccioni R, Labbaye C, Peschle C, Zollino M. Secondary leukemia responsive to retinoic acid with abnormal localization of RARa protein. A report of two cases. Blood 1998; 81: 4811–13
   Google Scholar
• Kurzrock R, Estey E, Talpaz M. All-transretinoic acid, tolerance and biological effects in myelodysplastic syndrome. J. Clin Oncol 1993; 11: 1489–95
   PubMed Web of Science ®Google Scholar
• Ganser A, Hoelzer D. Clinical use of hematopoietic growth factors in the myelodysplastic syndromes. Sem Hemat 1996; 33: 186–195
   PubMed Web of Science ®Google Scholar
• Cazzola M, Anderson J E, Ganser A, Hellstrom-Lindberg E. A patient-oriented approach to the treatment of myelodysplastic syndromes. Haematologica 1998; 83: 910–935
   PubMed Web of Science ®Google Scholar
• Cheson B D, Jasperse D M, Simon R, Friedman M A. A critical apparisal of low dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes. J Clin Oncol 1986; 4: 1857–64
   PubMed Web of Science ®Google Scholar
• Venditti A, Stasi R, Del Poeta G, Buccisano F, Aronica G, Bruno A, Pisani F, Caravita T, Masi M, Tribalto M. All-trans retinoic acid and low-dose cytosine arabinoside for the treatment of “poor prognosis” acute myeloid leukemia. Leukemia 1995; 9: 1121–25
   PubMed Web of Science ®Google Scholar
• Silverman L R, Holland J F, Weinberg R S, Alter B P, Davis R B, Ellison R R, Demakos E P, Cornell C J, Jr, Carey R W, Schiffer C. Effects of treatment with 5-Azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Leukemia 1993; 7(Suppl 1)21–28
   PubMed Web of Science ®Google Scholar
• Klimecki W, Heaton R, Glindman-Gibson. Amifostine suppresses apoptosis in myelodysplastic CD34+ cells and promotes progenitor growth via polyamine like effects. Blood 1997; 80(suppl. 1)520a
   Google Scholar
• List A F, Brasfield F, Heaton R, Glinsmann-Gibson B, Crook L, Taetle R, Capizzi R. Stimulation of hematopoiesis by amifostine in patients with myelodysplastic syndrome. Blood 1997; 90: 3364
   PubMed Web of Science ®Google Scholar
• Kantarjian H M, Estey E H, Keating M J. Treatment of therapy related leukemia and myelodysplastic syndrome. Hemat Oncol Clin North Am 1993; 7: 81–107
   PubMed Web of Science ®Google Scholar
• Kantarjian H M, Keating M J, Walters R S, Smith T L, Cork A, McCredie K B, Freireich E J. Therapy related leukemia and myelodysplastic syndromes. Clinical, cytogenetic, and prognostic features. J Clin Oncol 1986; 4: 1748–57
   PubMed Web of Science ®Google Scholar
• de Witte T, Muus P, De Pauw B, Haanen C. Intensive antileukemic treatement of patients younger than 65 years with myelodysplastic syndromes and secondary acute myelogenous leukemia. Cancer 1990; 66: 831–37
   PubMed Web of Science ®Google Scholar
• De Witte T, Suciu S, Peetermans M, Fenaux P, Strijckmans P, Hayat M, Jaksic B, Selleslag D, Zittoun R, Dardenne M, Solbu G, Zwierzina H, Huus P. Intensive chemotherapy for poor prognosis myelodyplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organization for Research and Treatment in Cancer (EORTC-LCG). Leukemia 1995; 9: 1805–1811
   PubMed Web of Science ®Google Scholar
• Larson R A, Wernli M, Le Beau M M, Daly K M, Pape L H, Rowley J D, Vardiman J W. Short remission durations in therapy related leukemia despite cytogenetic complete response to high high dose cytarabine. Blood 1988; 72: 1333–39
   PubMed Web of Science ®Google Scholar
• Preisler H D, Early A P, Raza A, Vlahides G, Marinello M J, Stein A M, Browman G. Therapy of secondary acute nonlymphocytic leukemia with cytarabine. New Engl J Med 1983; 308: 21–23
   PubMed Web of Science ®Google Scholar
• Larrea L, Martinez J A, Sanz G F, Martin G, de la Rubia J, Jimenez C, Jarque I, Cid A, Lopez A, Sanz M A. Carboplatin plus cytarabine in the treatment of high-risk acute myeloblastic leukemia. Leukemia 1999; 13: 161–65
   PubMed Web of Science ®Google Scholar
• Gardin C, Chaibi P, de Revel T, Rousselot P, Turlure P, Miclea J M, Nedellec G, Dombret H. Intensive chemotherapy with idarubicin, cytosine arabinoside, and granulocyte colony-stimulating factor (G-CSF) in patients with secondary and therapy related acute myelogenous leukemia. Leukemia 1997; 11: 16–21
   PubMed Web of Science ®Google Scholar
• Philpott N, Mehta J, Treleaven J, Powles R. Idarubicin, high dose Cytarabine and etoposide for remission induction in therapy related acute myeloid leukemia. Leuk Lymph 1994; 15: 127–30
   PubMed Web of Science ®Google Scholar
• Visani G, Tosi P, Zinzani P L, Manfroi S, Ottaviani E, Testoni N, Clavio M, Cenacchi A, Gamberi B, Carrara P, Gobbi M, Tura S. FLAG (Fludarabin plus high dose cytarabin plus G-CSF)- an effective and tolerable protocol for the poor acute myeloid leukemia. Leukemia 1994; 8: 1842–46
   PubMed Web of Science ®Google Scholar
• Byrne J L, Dasgupta E, Pallis M, Turzanski J, Forman K, Mitchell D, Haynes A P, Russell N H. Early allogeneic transplantation for refractory or relapsed leukaemia following remission induction with FLAG. Leukemia 1999; 13: 786–91
   PubMed Web of Science ®Google Scholar
• Sandier E S, Friedman D J, Mustafa M M, Winick N J, Bowman W P, Buchanan G R. Treatment of children with epipodophyllotoxin-induced secondary acute myeloid leukemia. Cancer 1997; 79: 1049–54
   PubMed Web of Science ®Google Scholar
• Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, Rees J, Hann I, Stevens R, Burnett A, Goldstone A. The importance of diagnostic cytogenetics on outcome in AML. analysis of 1612 patients enterd into MRC AML 10 trial. Blood 1998; 92: 2322–33
   PubMed Web of Science ®Google Scholar
• Cortes J, O'Brien S, Kantarjian H, Cork A, Stass S, Freireich E J, Keating M, Pierce S, Estey E. Abnormalities in the long arm of chromosome II (11q) in patients with de novo and secondary acute myelogenous leukemias and myelodysplastic syndromes. Leukemia 1994; 8: 2174–78
   PubMed Web of Science ®Google Scholar
• Harrison C, Hudson G V, Devereux S, Linch D C. Outcome of secondary myeloid malignancy in Hodgkins's disease, the BNLI experience. Eur J Haematol 1998; 61: 109–112
   PubMed Web of Science ®Google Scholar
• De Witte T, Van Biezen A, Hermans J, Labopin M, Runde V, Or R, Meloni G, Mauri S B, Carella A, Apperley J, Gratwohl A, Laporte J. Autologous bone marrow transplantation for patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia following MDS. Blood 1997; 90: 3853–57
   PubMed Web of Science ®Google Scholar
• De Witte T, Zwaan F, Hermans J, Vernant J, Kolb H, Vossen J, Lonnqvist B, Beelen D, Ferrant A, Gmur J. Allogenic bone marrow transplantation for secondary leukemia and myelodysplastic syndrome, a survey by the Leukemia Working Party of the European Bone Marrow Transplantation Group (EBMTG). Brit J Haemal 1990; 74: 151–55
   PubMed Web of Science ®Google Scholar
• Longmore G, Guinan E C, Weinstein H J, Gelber R D, Rappeport J M, Antin J H. Bone marrow transplantation for myelodysplasia and secondary acute non lymphoblastic leukemia. J Clin Oncol 1990; 8: 1707–14
   PubMed Web of Science ®Google Scholar
• Bandini G, Rosti G, Calori E, Albertazzi L, Tura S. Allogenic bone marrow transplantation for secondary leukemia and myelodysplastic syndrome. Br J Haematol 1990; 75: 442–43
   PubMed Web of Science ®Google Scholar
• Ratanatharathorn V, Karanes C, Uberti J, Lum L G, de Planque M M, Schultz K R, Cronin S, Dan M E, Mohamed A, Hussein M. Busulfan based regimens and allogenic bone marrow transplantation in patients with myelodysplastic syndromes. Blood 1993; 81: 2194–9
   PubMed Web of Science ®Google Scholar
• O'Donnell M R, Long G D, Parker P M, Niland J, Nademanee A, Atnylon M, Chao N, Negrin R S, Schmidt G M, Slovak M L. Busulfan and cyclophosphamide as conditioning regimen for allogenic bone marrow tranplantation for myelodysplasia. J Clin Oncol 1995; 13: 2973–9
   PubMed Web of Science ®Google Scholar
• Anderson J E, Anasetti C, Appelbaum F R, Schoch G, Gooley T A, Hansen J A, Buckner C D, Sanders J E, Sullivan K M, Storb R. Unrelated donor marrow transplantation for myelodysplasia (MDS) and MDS-related acute myeloid leukemia. Brit J Hematol 1996; 93: 59–67
   PubMed Web of Science ®Google Scholar
• Arnold R, de Witte T, van Biezen A, Hermans J, Jacobsen N, Runde V, Gratwohl A, Apperley J F. Unrelated bone marrow transplantation in patients with myelodysplastic syndromes and secondary acute myeloid leukemia, an EBMT survey. Bone Marrow Transplant 1998; 21: 121
   Web of Science ®Google Scholar
• Leahey A M, Friedman D L, Bunin N J. Bone Marrow transplantation in pediatric patients with therapy-related myelodysplasia and leukemia. Bone Marrow Transplant 1999; 23: 21–25
   PubMed Web of Science ®Google Scholar
• Anderson J E, Thomas E D. The Seattle experience with bone marrow transplantation (BMT) for myelodysplasia (MDS). Abstract. Leuk Res 1997; 21(suppl. 1)S51
   PubMedGoogle Scholar
• Appelbaun F R, Anderson J. Allogenic bone marrow transplantation for myelodysplastic syndrome, outcomes analysis according to IPSS score. Leukemia 1998; 12(suppl 1)S25–29
   PubMedGoogle Scholar
• Anderson J E, Gooley T A, Schoch G, Anasetti C, Bensinger W I, Clift R A, Hansen J A, Sanders J E, Storb R, Appelbaum F R. Stem cell transplantation for secondary acute myeloid leukemia, evaluation of transplantation as initial therapy or following induction chemotherapy. Blood 1997; 89: 2578–85
   PubMed Web of Science ®Google Scholar
• Witherspoon R P, Deeg H J. Allogenic bone marrow transplantation for secondary leukemia or myelodysplasia. Haematologica 1999; 84: 1085–87
   PubMed Web of Science ®Google Scholar
• Runde V, de Witte T, Arnold R, Gratwohl A, Hermans J, van Biezen A, Niederwieser D, Labopin M, Walter-Noel M P, Bacigalupo A, Jacobsen N, Ljungman P, Carreras E, Kolb H J, Aul C, Apperley J. Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes, early transplantation is associated with improved outcome. Bone Marrow Transplant 1998; 21: 255–61
   PubMed Web of Science ®Google Scholar
• Ballen K K, Gilliland D G, Guinan E C, Hsieh C C, Parsons S K, Rimm I J, Ferrara J L, Bierer B E, Weinstein H J, Antin J H. Bone marrow transplantation for therapy-related myelodysplasia. comparison with primary myelodysplasia. Bone Marrrow Transplant 1997; 20: 737–43
   PubMed Web of Science ®Google Scholar
• Friedberg J W, Neuberg D, Stone R M, Alyea E, Jallow H, LaCasce A, Mauch P M, Gribben J G, Ritz J, Nadler L M, Soiffer R J, Freedman A S. Outcome in patients with myelodysplastic syndrme after autologous bone marrow trasnplantation for non-Hodgkin's lymphoma. J Clin Oncol 1999; 17: 3128–3135
   PubMed Web of Science ®Google Scholar